On April 28, 2014, InVivo Therapeutics (NASDAQ:NVIV) announced something that investors have been waiting on for a very long time - the biocompatible polymer scaffolding has finally entered human clinical trials for the treatment of acute spinal cord injury. We remind investors that implantation of the Neuro-Spinal Scaffold ("NSS") device in preclinical rodent and primate studies resulted in functional recovery for previously paralyzed animals. Recall some of the impressive videos the company made available in 2011 and 2012 from these studies. The company is hoping these results transition over to humans with the start of this potential revolutionary trial.
InVivo's NSS is made of a porous bioresorbable polymer scaffold comprised of poly ((lactic-co-glycolic acid)-co-poly-(L-lysine)), or PLGA-PLL. The device...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|